Abaxis (ABAX) Reports Q3 In-Line
More News related to ABAX
- Abaxis, Inc. to Present at Needham & Company's Eleventh Annual Growth Stock Conference
- FDA Grants Abaxis (ABAX) Waived Status Under CLIA for 2 Analytes, Creatine Kinase and Phosphorus
- Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
- Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
- Abaxis, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Abaxis, Inc. (Nasdaq: ABAX) reports Q3 EPS of $0.15, versus the analyst estimate of $0.15. Revenue for the quarter was $27.7 million, versus the consensus of $27.80 million.
Related Categories
EarningsStocks Mentioned
-0.57Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
